Dolutegravir Synthesis via Segmented Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing dolutegravir, an HIV-1 integrase inhibitor, are inefficient and lack novel intermediates, which hampers the production of this critical antiretroviral drug.
Innovation Solution
A novel synthetic process involving specific reactions such as reacting a compound of formula 8 with 1,1-dimethoxy-N,N-dimethyl methanamine, followed by cyclization with dimethyl oxalate, condensation with 2,4-difluorobenzylamine, and oxidation, generates novel intermediates to efficiently produce dolutegravir and its pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current synthesis methods are used, then dolutegravir can be produced, but the synthesis efficiency is low and no novel intermediates are generated
Solution Approach 1:
The synthesis process is divided into distinct stages with isolated intermediates (Formula 1-8) that can be independently optimized and characterized. Each reaction step produces a discrete intermediate structure that can be purified and stored separately, enabling modular process development and quality control.
Solution Approach 2:
The methodology prepares and characterizes novel intermediates (Formulas 1-8) in advance before final dolutegravir assembly. These pre-synthesized intermediates with defined stereochemistry and purity can be readily combined in subsequent steps, streamlining the overall production process and reducing final-stage complexity.
2Productivity
If existing processes are used, then dolutegravir production is maintained, but the method lacks efficiency and effectiveness
Solution Approach 1:
The synthesis methodology employs specific reaction parameters including temperature control, solvent selection, and catalyst optimization for each transformation step. These parameter optimizations enhance both reaction efficiency and product purity, ensuring reliable and effective dolutegravir production while improving overall synthesis productivity.
Solution Approach 2:
The process replaces traditional multi-step mechanical purification methods with optimized chemical transformation sequences that inherently produce higher purity intermediates. The systematic chemical approach substitutes for repetitive physical separation operations, improving both efficiency and reliability of the synthesis process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enhances the synthesis efficiency of dolutegravir, providing a more effective method for producing the drug and its salts, which is crucial for HIV treatment.
Implementation Method 1
reacting a compound of formula 8 with 1,1-dimethoxy-N,N-dimethyl methanamine to obtain a compound of formula 7
Implementation Method 2
treating the compound of formula 7 with an alkenyl amine to obtain a compound of formula 6
Implementation Method 3
cyclizing the compound of formula 6 with dimethyl oxalate to obtain a compound of formula 5
Implementation Method 4
converting the compound of formula 5 to a compound of formula 4
Implementation Method 5
condensing the compound of formula 4 with 2,4-difluorobenzylamine to obtain a compound of formula 3
Implementation Method 6
oxidizing the compound of formula 3 to obtain a compound of formula 2
Implementation Method 7
reacting the compound of formula 2 with (R)-3-aminobutanol to obtain a compound of formula 1
Implementation Method 8
converting the compound of formula 1 to dolutegravir
Data Source
AI summary
Processes for the preparation of dolutegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed. Intermediates in those synthetic schemes are also disclosed.